The anticipated growth is mainly driven by ten new pipeline drugs expected to be introduced to the market by 2034.

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo ® for intravenous administration in the treatment of moderate to severe SLE. If approved, a ...

Patients with systemic lupus erythematosus who receive belimumab monotherapy show comparable remission rates and disease control to those who receive combination therapy with immunosuppressants.

Skin manifestations are common in patients with SLE. A recent study reported increased site-specific recurrence of cutaneous lupus erythematosus (CLE).1 While this study included a proportion of ...

The presence of autoantibodies in apparently healthy individuals has been increasingly recognized. Although some of these individuals are in preclinical stages of a disease such as systemic lupus ...

Discrimination was linked to increased systemic lupus erythematosus symptom burden, mediated by symptoms of depression and ...

Data suggest incidence and prevalence of systemic lupus erythematosus (SLE) vary widely among regions, although the authors noted some regions have been studied more extensively than others. A new ...

As The European Lupus Society’s 15th annual soiree approaches, the Clinical Trials Arena team takes a look at four promising therapies in the SLE pipeline.

Worldwide incidence and prevalence estimates of systemic lupus erythematosus (SLE) vary substantially and are influenced by ethnic and geographic differences, study design and environmental exposures ...

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...